Literature DB >> 7591967

Hyperfractionated and hypofractionated radiation therapy for human malignant glioma xenograft in nude mice.

M Hasegawa1, H Niibe, N Mitsuhashi, M Yamakawa, S Kato, M Furuta, T Kazumoto, K Hayakawa, Y Nakazato.   

Abstract

Xenografts of a human malignant glioma subcutaneously transplanted into nude mice were irradiated with graded single doses (2, 5, 10 or 20 Gy) or five types of fractionation schedules in two weeks: conventional [20 Gy in 10 fractions (fr)], hyperfractionated [24 Gy in 20 fr (two fractions per day)], and hypofractionated-1, 2, 3 [20 Gy, 18 Gy, 16 Gy in 4 fr]. All of the fractionated irradiation groups showed tumor regression. The hypofractionation-1 group (20 Gy in 4 fr) demonstrated the most prominent tumor regression, while the hyperfractionation group (24 Gy in 20 fr) showed the least effect. The hypofractionation-2 group (18 Gy in 4 fr) showed similar regression to the conventional fractionation group (20 Gy in 10 fr). Histologically, tumors in the control groups consisted of a homogenous population of small anaplastic cells, and only a small number of tumor cells were glial fibrillary acidic protein (GFAP)-positive. Following irradiation, the population of small anaplastic cells decreased and the percentage of GFAP-positive cells increased. Cellular pleomorphism became much more prominent after irradiation in all of the fractionated irradiation groups as compared with the graded single dose irradiation groups. In this study, hyperfractionation was not effective against human glioma xenografts compared with conventional fractionation and hypofractionation. This indicates that care is needed in applying hyperfractionation regimens to human malignant gliomas.

Entities:  

Mesh:

Year:  1995        PMID: 7591967      PMCID: PMC5920924          DOI: 10.1111/j.1349-7006.1995.tb03100.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  26 in total

1.  Superfractionated radiotherapy in grade III, IV intracranial gliomas.

Authors:  C M Ludgate; B G Douglas; P F Dixon; P Steinbok; S M Jackson; G B Goodman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-11       Impact factor: 7.038

2.  Distribution of radiation sensitivities for human tumor cells of specific histological types: comparison of in vitro to in vivo data.

Authors:  E P Malaise; B Fertil; N Chavaudra; M Guichard
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-04       Impact factor: 7.038

Review 3.  The first James Kirk memorial lecture. What next in fractionated radiotherapy?

Authors:  J F Fowler
Journal:  Br J Cancer Suppl       Date:  1984

4.  Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma.

Authors:  M Deutsch; S B Green; T A Strike; P C Burger; J T Robertson; R G Selker; W R Shapiro; J Mealey; J Ransohoff; P Paoletti
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-06       Impact factor: 7.038

5.  Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma.

Authors:  K E Wallner; J H Galicich; G Krol; E Arbit; M G Malkin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-06       Impact factor: 7.038

6.  Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study.

Authors:  C R Freeman; J P Krischer; R A Sanford; M E Cohen; P C Burger; R del Carpio; E C Halperin; L Munoz; H S Friedman; L E Kun
Journal:  Int J Radiat Oncol Biol Phys       Date:  1993-09-30       Impact factor: 7.038

7.  Assumptions in the radiotherapy of glioblastoma.

Authors:  F H Hochberg; A Pruitt
Journal:  Neurology       Date:  1980-09       Impact factor: 9.910

8.  Misonidazole combined with hyperfractionation in the management of malignant glioma.

Authors:  D S Fulton; R C Urtasun; K H Shin; P H Geggie; H Thomas; P J Muller; J Moody; H Tanasichuk; B Mielke; E Johnson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-09       Impact factor: 7.038

9.  Hyperfractionated radiation therapy for gliomas of the brainstem in children and in adults.

Authors:  D C Shrieve; W M Wara; M S Edwards; P K Sneed; M D Prados; P H Cogen; D A Larson; V A Levin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

10.  Correlations between cytologic composition and biologic behavior in the glioblastoma multiforme. A postmortem study of 50 cases.

Authors:  F Giangaspero; P C Burger
Journal:  Cancer       Date:  1983-12-15       Impact factor: 6.860

View more
  2 in total

1.  Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1).

Authors:  Mariangela Massaccesi; Marica Ferro; Savino Cilla; Mario Balducci; Francesco Deodato; Gabriella Macchia; Vincenzo Valentini; Alessio G Morganti
Journal:  Int J Clin Oncol       Date:  2012-08-15       Impact factor: 3.402

Review 2.  Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields.

Authors:  Shiyu Liu; Qin Zhao; Weiyan Shi; Zhuangzhuang Zheng; Zijing Liu; Lingbin Meng; Lihua Dong; Xin Jiang
Journal:  J Cancer       Date:  2021-01-01       Impact factor: 4.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.